

Please type a plus sign (+) inside this box ☐Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
Application Number			10/022,276		
Filing Date			December 14, 2001		
First Named Inventor			Gosselin, <i>et al.</i>		
Group Art Unit			1623		
Examiner Name			L. Eric Crane		
Attorney Docket Number			06171.105005 (NOV 1000CON)		
Sheet	1	of	4		

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
Me	DA	WO	96/11204	A1	Matthes et al.	04-18-1996		
Me	DB	EP	0 352 248	A1	Medivir Aktiebolag	01-24-1990		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
Me	DC	ARNER and ERIKSSON, "Mammalian Deoxyribonucleoside Kinases," <i>Pharm. Ther.</i> , 1995, 67(2), 155-186.	
	DD	BERK et al., "A Genetically Distinct Tymidine Kinase in Mammalian Mitochondria," <i>J Biol Chem</i> , 1973, 248, 2722-2729. (Issue No. 8, 04/25/73).	
	DE	BESTWICK et al., "Selective Expansion of Mitochondrial Nucleoside Triphosphate Pools in Antimetabolite-treated HeLa Cells," <i>J Biol Chem</i> , 1982, 257, 9300-9304. (No. 6; 8/25/82).	
Me	DF	BRIDGES et al., "Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria," <i>J. Biol. Chem</i> , February 19, 1999, 274(8), 4620-4625.	

! Month of publication data could not be determined from the copy supplied.

Examiner Signature	L. E. Crane <i>LE Crane</i>	Date Considered	09/16/02
--------------------	-----------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/022,276
				Filing Date	December 14, 2001
				First Named Inventor	Gosselin, <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	L. Eric Crane
				Attorney Docket Number	06171.105005 (NOV 1000CON)
Sheet	2	of	4		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>		
Me	DG	BRIDGES et al., "Identification of a novel mitochondrial dNTP carrier and its interaction with anti-HIV nucleoside analogs," <i>Proc. Am. Assoc. Cancer Res.</i> , March 1997, 38, Abstr. No. 414, p. 62			
Me	DH	BRIDGES et al., "Inhibition of Mammalian DNA Polymerase-Associated 3' to 5' Exonuclease Activity by 5'-Monophosphates of 3'-Azido-3'-Deoxythymine and 3'-Amino-3'-Deoxythymidine," <i>Biochemical Pharmacology</i> , 1993, 45(8), 1571-1576.			
	DI	CHARIOT et al., "Zidovudine-induced mitochondrial disorder with massive liver steatosis myopathy, lactic acidosis, and mitochondrial DNA depletion," <i>J. Hepatology</i> , 1999, 30, 156-160.			
	DJ	CHANG et al., "Biochemical Pharmacology of (+)- and (-)-2',3'-Dideoxy-3'-thiacytidine as Anti-hepatitis B Virus Agents," <i>J Biol Chem</i> , November 5, 1992, 267(31), 22414-22420.			
	DK	CHEN et al., "Characterization of Pyrimidine Deoxyribonucleoside Kinase (Thymidine Kinase) and Thymidylate Kinase as a Multifunctional Enzyme in Cells Transformed by Herpes Simplex Virus Type 1 and in Cells Infected with Mutant Strains of Herpes Simplex Virus," <i>J Virol</i> , June 1979, 30, 942-945.			
	DL	CHEN et al., "Delayed Cytotoxicity and Selective Loss of Mitochondrial DNA in Cells Treated with the Anti-human Immunodeficiency Virus Compound 2',3'-Dideoxycytidine," <i>J Biol Chem</i> , 1989, 264, 11934-11937. (Issue No. 20; July 15, 1989).			
	DM	CHEN et al., "The Role of Cytoplasmic Deoxycytidine Kinase in the Mitochondrial Effects of the Anti-human Immunodeficiency Virus Compound 2',3'-Dideoxycytine," <i>J Biol Chem</i> , February 15, 1992, 267(5), 2856-2859.			
	DN	CUI et al., "Effect of Nucleoside Analogs on Neurite Regeneration and Mitochondrial DNA Synthesis in PC-12 Cells," <i>J. of Pharmacology and Experimental Therapeutics</i> , 1997, 280(3), 1228-1234.			
	DO	DAVIS et al., "In Situ Localization of Mitochondrial DNA Replication in Intact Mammalian Cells," <i>J Cell Biol</i> , 1996, 135, 883-893. (Issue No. 4; November, 1996).			
Me	DP	DOONG et al., "Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues," <i>Proc. Natl. Acad. Sci.</i> , October 1991, 88, 8495-8499.			

! Month of publication data could not be determined from the copy supplied.

Examiner Signature	L. E. Crane	Date Considered	09/16/02
--------------------	-------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/022,276
				Filing Date	December 14, 2001
				First Named Inventor	Gosselin, et al.
				Group Art Unit	1623
				Examiner Name	L. Eric Crane
				Attorney Docket Number	06171.105005 (NOV 1000CON)
Sheet	3	of	4		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
Jce	DQ	DUTSCHMAN et al., "Metabolism of 2',3'-dideoxy-2',3'-didehydro-β-L-(-)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Humna Immunodeficiency Virus β-D-(+) Nucleoside Analogs In Vitro," <i>Antimicrobial Agents and Chemotherapy</i> , July 1998, 42(7), 1799-1804.		
	DR	HERNANDEZ-SANTIAGO et al., "Pharmacology of β-L-Thymidine and β-L-2'-Deoxycytidine in HepG2 Cell and Primary Human Hepatocytes: Relevance to Chemotherapeutic Efficacy against Hepatitis B Virus," <i>Antimicrobial Agents and Chemotherapy</i> , June 2002, 46(6), 1728-1733.		
	DS	JUROVČIK and HOLY "Metabolism of pyrimidine L-nucleosides," <i>Nucleic Acids Research</i> , August 1976, 3(8), 2143-2153.		
	DT !	KRAYEVSKY and CHERNOV, "Can a Substrate Enantiomer Be a Substrate for the Same Enzyme?," <i>Molecular Biology</i> , 1996, 30(5), 585-591.		
	DU !	KRAYEVSKY and CHERNOV, "Should the Asymmetric of Enzymatic Active Centers Always Correlate with the Asymmetry of their Substrates?," <i>J. of Bionolecular Structure &amp; Dynamics</i> , 1996, 14(2), 225-230.		
	DV !	LABENZ et al., "Analysis of the TK Enzyme Complex Induced by HSV Types 1 and 2 by Means of Isoelectric Focusing and Polyacrylamide Gel Electrophoresis," <i>Arch Virol</i> , 1982, 71, 235-249.		
	DW !	LIN et al., "Synthesis and Biological Evaluation of 2',3'-Dideoxy-L-pyrimidine Nucleosides as Potential Antiviral Agents against HIV and HBV," <i>J. Med. Chem</i> , 1994, 97, 798-803. (Issue No. 6)		
	DX	PAN-ZHOU et al., "Differential Effects of Antiretroviral Nucleoside Analogs on Mitochondrial Function in HepG2 Cells," <i>Antimicrobial Agents and Chemotherapy</i> , March 2000, 44(3), 496-503.		
	DY	PLACIDI et al., "Cellular pharmacology of β-L-thymidine and β-L-2'-deoxycytidine in HepG2 cells and primary rat, monkey and human hepatocytes," 3 <sup>rd</sup> Int. Conf. Ther. Vir. Hepatitis, abstr. A122, 1999 [Antivir. Ther. 4, Suppl. 4]. (December 12-16, 1999).		
Jce	DZ !	SODERLUND and ARNER, "Mitochondrial versus Cytosolic Activities of Deoxyribonucleoside Salvage Enzymes," <i>Purine and Pyrimidine Metabolism in Man VIII</i> , A.Shota & M. Taylor (ed.), Plenum Press, New York, 1995, 201-204.		

! Month of publication could not be determined from the copy supplied.

Examiner Signature	L. E. Crane <i>[Signature]</i>	Date Considered	09/16/02
--------------------	--------------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY FOR *[Signature]* File [ ] Applicant

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/022,276
				Filing Date	December 14, 2001
				First Named Inventor	Gosselin, <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	L. Eric Crane
				Attorney Docket Number	06171.105005 (NOV 1000CON)
Sheet	4	of	4		

[illegible]


Examiner Signature	L. E. Crane 	Date Considered	09/16/02
-----------------------	---	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

COPY FOR ☒ File ☐ Applicant

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of

1

**Complete if Known**

Application Number	10/022,276
Filing Date	December 14, 2001
First Named Inventor	Gosselin, et al.
Group Art Unit	1623
Examiner Name	L. Eric Crane
Attorney Docket Number	06171.105005 (IDX1000COM)

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
<i>Me</i>	FA	6,297,222	B1	von Borstel et al.	10-02-2001	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
<i>Me</i>	FB	WO	89/03838	A1	Pro-neuron, Inc.	05-05-1989		
<i>Me</i>	FC	EP	0 355 131	B1	Pro-neuron, Inc.	09-04-1996		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>

Examiner  
Signature

L. E. Crane

Date  
Considered

09/16/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.